Angiotensin AT2 receptors: cardiovascular hope or hype?
Widdop
Robert E
RE
Department of Pharmacology, Monash University, Melbourne, Victoria 3800, Australia. robert.widopp@med.monash.edu.au
Jones
Emma S
ES
Hannan
Ruth E
RE
Gaspari
Tracey A
TA
D057912:Angiotensin II Type 2 Receptor Blockers; D000818:Animals; D002320:Cardiovascular Physiological Phenomena / Q000187:drug effects; D006801:Humans; D044139:Receptor, Angiotensin, Type 2 / Q000502:physiology*; D013777:Tetrazoles / Q000494:pharmacology; D014633:Valine / Q000031:analogs & derivatives / Q000494:pharmacology; D000068756:Valsartan; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology*
D057912:Angiotensin II Type 2 Receptor Blockers; D044139:Receptor, Angiotensin, Type 2; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine